UCLA Institute for Precision Health

UCLA Institute for Precision Health
Name	UCLA Institute for Precision Health
Established	2017
Parent institution	University of California, Los Angeles
Location	Los Angeles, California
Director	Ami S. Bhatt

UCLA Institute for Precision Health is a multidisciplinary research center located at the University of California, Los Angeles focused on integrating genomics, bioinformatics, clinical data, and population health to advance individualized prevention and treatment strategies. The institute brings together investigators from medicine, public health, engineering, and data science to translate discoveries into clinical practice and public policy. It emphasizes large-scale cohort studies, electronic health record integration, and partnerships with health systems and community organizations to accelerate precision medicine.

History

The institute was launched within the University of California, Los Angeles ecosystem as part of broader investments in biomedical innovation alongside entities such as the David Geffen School of Medicine at UCLA, the UCLA Health system, and the Jonsson Comprehensive Cancer Center. Its formation followed national initiatives including the All of Us Research Program and governmental precision medicine efforts in the administration of Barack Obama. Founding activities incorporated faculty from units linked to the UCLA Fielding School of Public Health, the UCLA Henry Samueli School of Engineering and Applied Science, and the UCLA Broad Stem Cell Research Center, building on legacy programs like the California Precision Medicine Consortium and collaborations with centers such as the Cedars-Sinai Medical Center and Ronald Reagan UCLA Medical Center.

Mission and Research Focus

The institute's mission aligns with federal roadmaps exemplified by the Precision Medicine Initiative and international efforts like the Human Genome Project to leverage genomic and clinical data for individualized care. Research priorities include genomics, transcriptomics, microbiome science, pharmacogenomics, and computational biology, integrating methodologies from groups associated with the National Institutes of Health, the National Cancer Institute, and agencies engaged in translational science such as the Biomedical Advanced Research and Development Authority. Projects often intersect with clinical trials overseen by institutional review boards in the spirit of standards promoted by the World Health Organization and the National Academies of Sciences, Engineering, and Medicine.

Organization and Leadership

Leadership comprises clinicians and scientists drawn from prominent UCLA units and external advisors affiliated with institutions like the Broad Institute, Stanford University School of Medicine, and Harvard Medical School. Directors coordinate with department chairs in Department of Medicine, UCLA, the Department of Human Genetics, UCLA, and the UCLA Department of Computer Science. Governance includes advisory boards populated by representatives from the California Institute for Regenerative Medicine, industry partners such as Genentech, Illumina, and philanthropic stakeholders resembling the UCLA Health Sciences Advancement donors network.

Major Programs and Initiatives

Flagship programs parallel national cohorts like the Framingham Heart Study and engage in cancer-focused efforts akin to those at the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Initiatives encompass population cohorts, biobanking modeled after the UK Biobank, pharmacogenomics consortia with pharmaceutical partners such as Pfizer and Roche, and digital health collaborations with technology entities including Google Health and IBM Watson Health. The institute supports training programs and fellowships comparable to those at the Mayo Clinic and the Johns Hopkins School of Medicine to cultivate translational investigators.

Facilities and Resources

Physical resources include wet labs, high-throughput sequencing platforms similar to equipment used at the Broad Institute, core facilities for mass spectrometry like those in the Salk Institute, and computational clusters echoing infrastructure at the Lawrence Berkeley National Laboratory. Biorepositories follow standards observed at the National Cancer Institute and maintain data environments interoperable with electronic health record systems used by partners such as Kaiser Permanente and Cedars-Sinai. Educational spaces host seminars with speakers from organizations including the American Association for Cancer Research and the American Society of Human Genetics.

Collaborations and Partnerships

Collaborative networks span academic centers including UCSF School of Medicine, University of Southern California, and Caltech, as well as public health agencies such as the Los Angeles County Department of Public Health and industry collaborators like Thermo Fisher Scientific and Microsoft. Partnerships extend to community organizations and patient advocacy groups modeled on alliances with the American Cancer Society, the Alzheimer's Association, and the American Heart Association to ensure research relevance and equitable engagement.

Impact and Notable Achievements

The institute has contributed to publications in journals comparable to Nature Medicine, The New England Journal of Medicine, and Science Translational Medicine reporting advances in genomic risk prediction, microbiome associations, and pharmacogenomic implementation. It has facilitated translational projects that influenced clinical pathways in systems akin to UCLA Health and informed policy discussions at forums including the National Institutes of Health workshops. Training alumni have taken positions across institutions such as Massachusetts General Hospital, Stanford Health Care, and the University of Pennsylvania Health System.

Category:University of California, Los Angeles